IL37 and neoplasm: Finally, pathway analysis revealed that IL-37-signaling mediators, such as STAT3, are crucial partners of PD-1, PD-L1, and CTLA-4 pathways, providing hints for an interfering role of this cytokine in the immune-checkpoint blockade of anti-tumor immune responses.